Present Homologous and Heterologous Antigen with Hepatitis E Virus
Principal Investigator: R Holland Cheng
Abstract: DESCRIPTION (provided by applicant): Advantages of DNA vaccines including well-tolerance, safety and ability to induce antibody, cytotoxic T- lymphocytes, and T-helper immune responses make it more and more attractive in treatment of chronic virus infections. In order to successfully induce immune response, DNA vaccine needs to enter target cell for transcription and subsequent protein production. An ideal delivery carrier needs to be safe and effective in targeting specific cell, provide sufficient protection of DNA plasmid during transportation, as wel as low- responses to any existing self-immunity. Deficient viral particles, such as adenoviruses or retroviruses, offer an attractive option with great benefits in targeting and protection but majr drawbacks on strong self-immunity as well as the complexity in producing recombinant viral particles. Non-replicating virus-like particle derived from human hepatitis E virus (HEV-VLP) is empty icosahedral cage composed of 60 copies of recombinant HEV capsid proteins. This VLP is capable of encapsulating DNA vaccine in vitro, delivering DNA vaccine to epithelium cell at gastrointestinal tract, and inducing antigen-specific humoral and cellular immune responses. The simple procedure in DNA encapsulation makes HEV-VLP of particular interest as gene carrier;however, induction of self-immunity is still the hurdle in using HEV-VLP for therapeutical vaccination. Our studies on HEV-VLP crystal structure and antigenic structure reveal a structural modularity, with which HEV recombinant capsid proteins interplay between VLP assembly and antigen presentation. By carrying insertion of 15 amino acids at an antibody-binding site, the chimeric VLP reduces the reactivity to anti-HEV antibodies meanwhile retains the icosahedral assembly. This data suggests us a strategy to lower the reactivity of VLP to antibody- induced neutralization by structural alteration at antibody-binding sites, a mechanism that viruses have evolved to mediate their escape from host immune surveillance. The proposed experiments in this application include 1) using cryo-electron microscopy and image reconstruction to identify HEV-VLP surface flexible loops that critical to antibody interactions;2 inserting short peptide into the identified surface loops to create chimeric VLP with attenuate reactivity to HEV-VLP;3) both wild type and chimeric VLPs will be evaluated in delivery of DNA vaccine encoding the surface antigen of hepatitis B virus, as potential gene carrier for treatment of chronic progressive hepatitis B. Because HEV is an enteric transmitted virus, HEV-VLP is able to transcytose the mucosal barrier at gastrointestinal tract and target specific mucosal region for antigen production. When a short peptide bearing mucosal adhesion ligand is inserted into surface antigenic loops, the chimeric VLP is hypothesized to have strong specificity in targeting mucosal region, leading to potent induction of mucosal immunity. In collaboration with Dr Kit Lam and Dr Christopher Walker, two experts respectively in drug discovery and HBV vaccine development, we expect to obtain sufficient data leading us to repeated use of HEV-VLPs as carrier for clinical gene therapy.
Funding Period: -------------------- - --------------------
more information: NIH RePORT
- Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathwayLi Xing
Department of Molecular and Cellular Biology, University of California, Davis, California 95616, USA
J Biol Chem 285:33175-83. 2010..The in vitro assembly further demonstrated that HEV capsid protein had the intrinsic ability to form decameric intermediate. Our data suggest that RNA binding is the extrinsic factor essential for the assembly of HEV native capsids...
- Chimeric hepatitis E virus-like particle as a carrier for oral-deliveryPitchanee Jariyapong
Department of Molecular and Cellular Biology, University of California, Davis, CA 95616, United States
Vaccine 31:417-24. 2013..Therefore, the insertion of peptides at the surface antigenic site could allow VLPs to escape pre-existing anti-HEV humoral immunity...
- "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivoKai Xiao
Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, California 95817, USA
Cancer Res 72:2100-10. 2012..Therefore, OA02-targeted telodendrimers loaded with paclitaxel have great potential as a new therapeutic approach for patients with ovarian cancer...
- Calpains promote α2β1 integrin turnover in nonrecycling integrin pathwayNina Rintanen
Department of Biological and Environmental Science Nanoscience Center, University of Jyvaskyla, FI 40351 Jyväskylä, Finland
Mol Biol Cell 23:448-63. 2012..In conclusion, we identified a novel virus- and clustering-specific pathway that diverts α2β1 integrin from its normal endo/exocytic traffic to a nonrecycling, calpain-dependent degradative endosomal route...
- Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand bindingCarlos G Moscoso
Department of Molecular and Cellular Biology, University of California, Davis, CA 95616, USA
Proc Natl Acad Sci U S A 108:6091-6. 2011..Structural features gleaned from our studies should aid the design of Env-based immunogens for inducement of potent broadly neutralizing antibodies against exposed conformational epitopes...
- The structure of avian polyomavirus reveals variably sized capsids, non-conserved inter-capsomere interactions, and a possible location of the minor capsid protein VP4Peter S Shen
Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602, USA
Virology 411:142-52. 2011..However, the plug density is more prominent in APV and may include VP4, a minor capsid protein unique to bird polyomaviruses...
- Spatial configuration of hepatitis E virus antigenic domainLi Xing
Molecular and Cellular Biology, University of California, 1 Shields Ave, Davis, CA 95616, USA
J Virol 85:1117-24. 2011..Therefore, the T=1 HEV VLP is a novel delivery system for displaying foreign epitopes at the VLP surface in order to induce antibodies against both HEV and the inserted epitope...
- Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicityAzadeh Kheirolomoom
Department of Biomedical Engineering, 451 East Health Sciences Drive, School of Medicine, University of California, Davis, Davis, California 95616, United States
Mol Pharm 7:1948-58. 2010..After the 28-day course of therapy, syngeneic tumors regressed to a premalignant phenotype of ∼(1 mm)(3) or could not be detected...
- Structural evidence of glycoprotein assembly in cellular membrane compartments prior to Alphavirus buddingPan Soonsawad
Department of Molecular and Cellular Biology, University of California, Davis, CA 95616 8536, USA
J Virol 84:11145-51. 2010..Thus, the structural characteristics of CPV-II can be used in evaluating the design of a packaging cell line for replicon production...
- Structure of the arginine methyltransferase PRMT5-MEP50 reveals a mechanism for substrate specificityMeng Chiao Ho
Department of Biochemistry, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States of America
PLoS ONE 8:e57008. 2013..Electron microscopy and reconstruction showed substrate centered on MEP50. These data support a mechanism in which MEP50 binds substrate and stimulates PRMT5 activity modulated by substrate post-translational modifications...